BOP

BOP is anantagonist of alpha4beta1/alpha9beta1 integrins. BOP rapidly mobilizes long-term multi-lineage reconstituting hematopoietic stem cells (HSC).

BOP sodium salt is an inhibitor of alpha9beta1 and alpha4beta1 integrin.

I-BOP is an agonist (KD=0.61 nM) at the thromboxane A2 receptor (TP). I-BOP promotes cell proliferation by activating the PI3K pathway in vascular smooth muscle.

BOP-JF549 is a fluorescent dual α9β1/α4β1 integrin inhibitor. Comprises BOP conjugated to Janelia Fluor® 549. Fluorogenic: fluoresces only once bound to integrins, enabling hassle-free no-wash experiments. Bright and photostable, enabling live cell tracking of integrin receptors over long time-course experiments. Excitation maximum = 549 nm; emission maximum = 571 nm.

BOP-JF646 is a fluorescent dual α9β1/α4β1 integrin inhibitor. Comprises BOP conjugated to Janelia Fluor®646. Fluorogenic: fluoresces only once bound to integrins, enabling hassle-free no-wash experiments. Bright and photostable, enabling live cell tracking of integrin receptors over long time-course experiments. Excitation maximum = 655 nm; emission maximum = 672 nm.

BOP hexafluorophosphate is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity.

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation differentiation and platelet production.

TBOPP is a selective DOCK1 inhibitor (IC50 : 8.4 μM), with anti-tumor activity for broader types of tumors.

Fluoroclebopride is a dopamine (DA) D2 receptor ligand.

Clebopride malate is a dopamine antagonist used to treat functional gastrointestinal disorders, such as nausea or vomiting.

Ebopiprant (OBE022) is an orally available, selective and potent prostaglandin F2α (PGF2α) receptor antagonist that interferes with the binding of PGF0126α to the FPR and can be used in the study of obesity.

Carboprost tromethamine, a synthetic 15-methyl analogue of prostaglandin F2α, effectively promotes uterine contractions and significantly reduces bleeding during and post-delivery.

TCPOBOP, a constitutive androstane receptor agonist, induces robust hepatocyte proliferation and hepatomegaly while decreasing Fas-induced murine liver injury by altering Bcl-2 proteins.

Carboprost (15(S)-15-Methyl Prostaglandin F2α) is a synthetic analogue of PGF2α with oxytocic properties, commonly used to restore uterine tone.

Hetrombopag olamine is a non-peptide thrombopoietin (TPO) receptor agonist with oral activity.

Sibopirdine is a new type of cognitive enhancer and intelligence booster that has been studied as a cognitive enhancer for the treatment of Alzheimer's disease.

Bopindolol is a non-selective β-adrenergic receptor antagonist. In vivo, bopindolol decreases heart rate and blood pressure and attenuates ischemia-induced myocardial acidosis in dogs. Formulations containing bopindolol have been used to treat essential and renovascular hypertension.

(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC50 of 3.3 nM. It effectively mimics TPO by stimulating platelet production through activation of the intracellular signaling system, facilitating platelet and megakaryocyte generation from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 [CYP] 2C9 and CYP3A.

Hetrombopag is a potent agonist of the thrombopoietin receptor. Hetrombopag is well tolerated and has a controlled safety profile. hetrombopag has potential for studies in immune thrombocytopenia.